See article

Saccharomyces boulardii CNCM I-745: a unique single-strain yeast probiotic

  • Video
  • 3 min

What is Saccharomyces boulardii CNCM I-745?

Saccharomyces boulardii CNCM I-745 is a single-strain yeast probiotic. This specific yeast strain addresses the causes and symptoms of diarrhea as well as helps maintain the balance of beneficial microbiota.1

The multiple benefits of S. boulardii CNCM I-745 have been extensively demonstrated thanks to its long history as a probiotic.1

It was discovered by the French microbiologist Henri Boulard in 19231, who while in South East Asia, observed that people drinking a special tea made from the skins of mangosteens and litchis did not develop diarrhea.2

Since it was first discovered, the benefits of S. boulardii CNCM I-745 have been investigated in more than 100 clinical trials , and it has been available as a probiotic treatment for diarrhea for over 56 years.2 In fact, S. boulardii CNCM I-745 was the first yeast probiotic drug used in human medicine3.

S. boulardii CNCM I-745 is a non-pathogenic single-strain yeast probiotic that differs from other bacterial and yeast probiotics
due to its strain-specific properties, its proven specific mechanisms of action (MOA), as well as a unique manufacturing process and proven benefits backed by high quality scientific and clinical evidence.1,4

(Internal code : 20.15)

S. boulardii CNCM I-745 has many strain-specific qualities:

  1. It has a high tolerance to acid, meaning that it can pass through the stomach into the lower gastrointestinal tract without being destroyed.4
  2. Unlike other yeast members of the Saccharomyces family the ideal temperature for its growth is at the same temperature as the human body.4
  3. It is also naturally resistant to antibiotics5, meaning that it can be administered at the same time as antibiotics.
  4. It does not permanently colonise the gut so does not upset the normal balance of microbiota.1,4

Saccharomyces boulardii CNCM I-745 addresses the causes of diarrhea through multiple specific and proven mechanisms of action.4 It acts directly to counteract harmful microbes and their activity, enhances the gut’s immune response to these microbes, reduces inflammatory responses, and encourages a return to a healthy gut environment by restoring the balance of normal microbiota, as well as influencing normal gut processes that keep the gut working properly.1,4

In this way, S. boulardii CNCM I-745 is a solution for a complete approach to diarrhea, by addressing intestinal dysbiosis.

S. boulardii CNCM I-745 prevents and treats diarrhea as well as can restore intestinal microbiota following gut imbalance.6
 This yeast, which is registered as a drug in many countries due to its quality of scientific and clinical evidence, can:

  • prevent antibiotic-associated diarrhea when taken during antibiotic treatment6 ;
  • prevent recurrent Clostridium difficile disease6 ;
  • treat acute (infectious) diarrhea4 ;
  • reduce Helicobacter pylori eradication therapy-associated side effects6 ;
  • aid in the recovery of normal gut microbiota following an imbalance in composition and diversity1.

 

 

Internal code : 20.55

References

  • 01 . More MI, and Swidsinski, A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis–a review. Clinical and experimental gastroenterology. 2015; 8: 237.
  • 02 . Data on file_Biocodex_2019
  • 03 . Joly, F et al. 2017. Saccharomyces boulardii CNCM I-745. Marteau, P and Dore J (Ed.), Gut Microbiota: A full-fledged organ. 2017: 305-326. Paris: John Libbey Eurotext.
See more See less
  • 04 . McFarland, LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World journal of gastroenterology: WJG. 2010; 16(18): 2202.
  • 05 . Neut C, Mahieux S, and Dubreuil LJ. Antibiotic susceptibility of probiotic strains: is it reasonable to combine probiotics with antibiotics? Medecine et maladies infectieuses. 2017; 47(7): 477-483.
  • 06 . Czerucka D, and Rampal, P. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. World journal of gastroenterology. 2019; 25(18): 2188.
Find the brand name
in your country
We are present in more than 90 countries
Some related
questions
  • Is Saccharomyces boulardii CNCM I-745 a probiotic?
    ExpandCollapseSee more
  • Is Saccharomyces boulardii CNCM I-745 a living organism?
    ExpandCollapseSee more
  • What is the name of the product in my country?
    ExpandCollapseSee more
You are
Country
Choose language